Pillstats
Rx only · Capsule, Delayed Release Pellets · Oral

Esomeprazole Magnesium

Esomeprazole Magnesium

5 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US9 NDCs
5 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)283742
US makers5 labelers
Packages27
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 7 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.045$0.090$0.136$0.181Dec 2025Apr 2026Jul 2026
$0.141
Latest avg · Jul 22, 2026
-10%
Since Dec 17, 2025
5
Active US suppliers
52%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

2855698541.1K2025 Q12025 Q22025 Q32025 Q42026 Q1
766
Rx · 2026 Q1
32K
Units dispensed
-9%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it5 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Bryant Ranch Prepackrepackager8SUPPLYING
Lannett Company, Inc.unknown6SUPPLYING
Glenmark Pharmaceuticals Inc., USAunknown6SUPPLYING
Mylan Pharmaceuticals Inc.unknown4SUPPLYING
A-S Medication Solutionsunknown3SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Oct 23, 2023
    RECALLRecall (Class III): Esomeprazole Magnesium Delayed-Release Capsules, USP 20mg, Packaged as (a) 30-count bottle, NDC 68462-390-30; (b) 1000-…

    Failed Impurities/Degradation Specifications:Out of Specification result reported for the test of organic impurities for the drug product,at the 18 month time point in long term stability study (25¿C/60% RH). — Recalling firm: Glenmark Pharmaceuticals Inc., USA — Nationwide in the USA